Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2023-03-29 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the regulator that does not fit into the other specialized categories like Director's Dealing or Share Issue.
2023-03-29 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filing from a Korean company (Genome & Company). It contains structured financial tables including audit opinions, balance sheet data, and income statement data for the current and previous fiscal years. While it provides financial data, it is a regulatory disclosure of the audit report's submission rather than the full, multi-page audited financial statements themselves. Under the provided definitions, this fits the 'Audit Report / Information' (AR) category as it specifically reports on the audit opinion and financial summary related to the audit process. FY 2022
2023-03-21 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for '주식회사 지놈앤컴퍼니' (Genome & Company) covering the fiscal year 2022 (2022.01.01 ~ 2022.12.31). It contains detailed sections on company overview, history, capital changes, and research and development pipelines. This structure corresponds to the standard Korean Annual Report (10-K equivalent) filed with the Financial Supervisory Service (FSS). FY 2022
2023-03-21 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a '정정신고' (Correction Report) regarding previously reported stock option grants. It details changes to the number of recipients, exercise prices, and total stock option status. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of share/capital changes.
2023-03-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically identified as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of shares, exercise prices, and the list of recipients. This type of filing is a standard regulatory disclosure regarding capital structure and employee compensation instruments, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2023-03-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details changes to previously granted stock options, including adjustments to the number of shares, exercise prices, and the list of recipients due to employee departures. This type of disclosure regarding stock option grants and their subsequent amendments is a standard regulatory requirement for listed companies, falling under the category of general regulatory filings as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes).
2023-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.